Fennec Pharmaceuticals (FENC) EBIAT (2016 - 2025)
Fennec Pharmaceuticals filings provide 15 years of EBIAT readings, the most recent being -$4.8 million for Q4 2025.
- On a quarterly basis, EBIAT fell 141.16% to -$4.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$9.7 million, a 2134.4% decrease, with the full-year FY2025 number at -$9.7 million, down 2134.17% from a year prior.
- EBIAT hit -$4.8 million in Q4 2025 for Fennec Pharmaceuticals, down from -$638000.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of $12.8 million in Q1 2024 to a low of -$8.0 million in Q3 2022.
- Median EBIAT over the past 5 years was -$4.2 million (2021), compared with a mean of -$3.3 million.
- The widest YoY moves for EBIAT: up 312.11% in 2024, down 207.18% in 2024.
- Fennec Pharmaceuticals' EBIAT stood at -$4.2 million in 2021, then crashed by 63.58% to -$6.9 million in 2022, then surged by 61.1% to -$2.7 million in 2023, then grew by 25.99% to -$2.0 million in 2024, then plummeted by 141.16% to -$4.8 million in 2025.
- The last three reported values for EBIAT were -$4.8 million (Q4 2025), -$638000.0 (Q3 2025), and -$3.2 million (Q2 2025) per Business Quant data.